News & Updates

Gout, hyperuricaemia meds less common among diabetics on SGLT2is
Gout, hyperuricaemia meds less common among diabetics on SGLT2is
28 Aug 2022

Patients with type 2 diabetes mellitus (T2DM) taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) are less likely to be prescribed antigout or antihyperuricaemic drugs, a recent study has found.

Gout, hyperuricaemia meds less common among diabetics on SGLT2is
28 Aug 2022
Dulaglutide safely controls glucose in T2D with CKD
Dulaglutide safely controls glucose in T2D with CKD
28 Aug 2022

In patients with type 2 diabetes (T2D) with chronic kidney disease (CKD), once-weekly dosage with dulaglutide achieves adequate glycaemic control along with a reduced decline in estimated glomerular filtration rate (eGFR), reports a recent study.

Dulaglutide safely controls glucose in T2D with CKD
28 Aug 2022
Early transition to oral antimicrobials prevents treatment failure in children with SAB, AHO
Early transition to oral antimicrobials prevents treatment failure in children with SAB, AHO
27 Aug 2022
Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
26 Aug 2022

Use of pimavanserin appears to be more effective than atypical antipsychotic agents in reducing mortality among Parkinson’s disease patients during the first 180 days of treatment, reveals a study. However, such benefit is seen only in community-dwelling patients and not in nursing home residents.

Pimavanserin trumps atypical antipsychotics in preventing death in Parkinson’s disease patients
26 Aug 2022